Moderna (MRNA) Current Deferred Revenue (2016 - 2026)

Moderna (MRNA) has 11 years of Current Deferred Revenue data on file, last reported at $102.0 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $102.0 million, down 18.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.0 million (down 18.4% YoY), and the FY2025 annual result was $252.0 million, up 64.71% from the prior year.
• Current Deferred Revenue fell to $102.0 million in Q1 2026 per MRNA's latest filing, from $252.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $6.1 billion in Q1 2022 and troughed at $20.0 million in Q2 2024.
• A 5-year average of $1.4 billion and a median of $568.0 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue tumbled 98.85% in 2024, then surged 990.0% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $2.7 billion in 2022, then plunged by 79.05% to $568.0 million in 2023, then plunged by 73.06% to $153.0 million in 2024, then jumped by 64.71% to $252.0 million in 2025, then slumped by 59.52% to $102.0 million in 2026.
• Business Quant data shows MRNA's Current Deferred Revenue at $102.0 million in Q1 2026, $252.0 million in Q4 2025, and $163.0 million in Q3 2025.